The impact of additive or substitutive clinical study design on the negotiated reimbursement for oncology pharmaceuticals after early benefit assessment in Germany

Abstract Background We analysed the impact of clinical study design for oncological pharmaceuticals on the subsequent price negotiations after early benefit assessment between pharmaceutical companies and the German National Association of Statutory Health Insurance Funds. The analysis was conducted...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: C. M. Dintsios, I. Beinhauer
Format: Artigo
Sprache:Inglês
Veröffentlicht: BMC 2020-03-01
Schriftenreihe:Health Economics Review
Schlagworte:
Study design
Negotiated prices
Oncological drugs
Pharmaceutical companies
Payers
German statutory health insurance
Online Zugang:http://link.springer.com/article/10.1186/s13561-020-00263-2
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge